37 results about "Antidote" patented technology

The invention belongs to the technical field of cytotoxicity intervention, and particularly relates to application of an inhibitor JSH-23 in preparation of a medicine for preventing and / or treating ovarian toxicity caused by environmental toxin combined exposure. Aiming at the condition that MC-LR and NaNON combined exposure can activate NF-kappa B to induce KK-1 cell nitrification stress and cause mouse ovarian dysfunction, JSH-23 is selected as an intervention agent, and it is found that after KK-1 cells are pretreated by JSH-23, NF-kappa B nuclear translocation induced by the KK-1 cells due to MC-LR and NaNON combined exposure is remarkably inhibited, iNOS protein rising induced by toxin combined exposure is remarkably reduced, and NF-kappa B nuclear translocation induced by the KK-1 cells due to NF-kappa B combined exposure is remarkably inhibited. The increase of the levels of ONOO and 3-NT of nitration stress markers is effectively relieved, which indicates that JSH-23 can participate in the nitration stress of KK-1 cells caused by combined exposure of MC-LR and NaNO2 by inhibiting NF-kappa B activation, and a foundation is laid for screening antidotes after exposure of environmental toxins.

The present application relates to a kind of macromolecular heavy metal complexing agent containing 8-hydroxyquinoline and amido phosphate structure and its preparation method, the present application also relates to a kind of heavy metal antidote, and the use of the macromolecular heavy metal complexing agent of the present application in preparing drug for treating heavy metal poisoning.The macromolecular complexing agent of the present application has excellent binding capacity with cadmium, lead, mercury and other heavy metal ions, and is high in safety, has excellent and long-acting heavy metal protection effect.The preparation method of the present application can mass, simply and efficiently prepare the macromolecular complexing agent of the present application, and preparation process is simple, high in yield, raw material is cheap and easy to obtain, reaction condition is mild.

In alternative embodiments, provided are polyheterocyclic uncharged bisoxime antidotes, including polyheterocyclic uncharged bisoximes, and methods for treating, preventing or ameliorating excessive acetylcholine stimulation in the brain comprising administering to an individual in need thereof a polyheterocyclic uncharged bisoxime antidote as provided herein. In alternative embodiments, provided are methods for treating, preventing or ameliorating excessive acetylcholine stimulation in the brain; or, treating, ameliorating or protecting (preventing) an organophosphate toxicity or poisoning or toxic exposure, or for treating, ameliorating or protecting (preventing) organophosphate inhibition of an acetylcholinesterase (AChE) comprising administering to an individual in need thereof a polyheterocyclic uncharged bisoxime antidote as provided herein.

The present disclosure relates to solutions and methods of preparing lyophilized formulations of factor Xa (fXa) antidotes. A suitable aqueous formulation suitable for lyophilization can include a fXa antidote, a solubilizing agent, a stabilizer, and a crystalline component, wherein the formulation does not collapse during lyophilization.

The invention relates to a nucleic acid aptamer DNA sequence as shown in SEQ ID NO.1 or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the nucleic acid aptamer sequence or the pharmaceutically acceptable salt thereof as an active ingredient. The invention also discloses application of the nucleic acid aptamer sequence or the pharmaceutically acceptable salt thereof in preparation of antidote drugs used as ricin and / or abrus precatorius toxin.

This invention provides the use of β-glucuronidase in the preparation of an antidote for the prevention and / or treatment of zearalenone poisoning, and an antidote for the prevention and / or treatment of zearalenone poisoning, belonging to the field of feed additives. This invention, for the first time from the perspective of in vivo exposure control in animals, proposes a method to reduce the overall ZEN exposure level by inhibiting the activity of intestinal bacterial β-glucuronidase. The technical path is clear and highly operable. This is achieved through in vivo toxicokinetic parameters (AUC, C...). max Changes in (and / or MRT) objectively reflect a reduction in ZEN exposure levels in vivo, and the technical effects are quantifiable and verifiable. The β-glucuronidase inhibitors used in this invention are widely available, particularly suitable for the field of feed additives, and have promising application prospects.

The present invention relates unit dose formulations of antidotes to anticoagulants targeting factor Xa. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.

Detonation nanodiamond nanocarrier platforms to transport quaternary oxime antidotes into the central nervous system have been developed. The nanodiamond-based AChE reactivators contain an organophosphorus poisoning antidote (e.g., a 4-hydroximinopyridinium moiety) bound to a biocompatible linker covalently attached to the nanodiamonds. These functionalized nanodiamonds successfully cross the layer of Madin-Darby Canine Kidney (MDCK) cells, the epithelial cell surrogate BBB model, and demonstrate a measurable dose-independent in vitro reactivation capacity towards human AChE inhibited by toxic organophosphorus compounds.

The application discloses application of a compound SCH23390 in preparation of a medicine for treating lead poisoning, and relates to the technical field of medicines. The application studies the efficiency of the compound SCH23390 in treatment of lead poisoning, first discloses the treatment effect of the compound SCH23390 on lead poisoning, breaks through the limitation of an existing drug target point, directly corrects abnormal nerve signals by inhibiting excessive activation of D1 neurons, avoids side effects of central excessive excitation, and has no significant toxic side effects under a treatment dose. In particular, the compound SCH23390 can significantly relieve specific abnormal behavior phenotypes caused by low-dose lead poisoning, and exhibits better neuroprotective characteristics than traditional chelating agents. The application breaks through the limitation of a single chelating antidote in the traditional field of lead poisoning treatment, and provides a new direction for development of anti-lead toxicity medicines with multiple target points and multiple mechanisms.

The invention belongs to the technical field of medicine separation, and particularly relates to magnetic bead immobilized snake venom phospholipase A2 as well as a preparation method and application thereof. The preparation method comprises the following steps: carrying out a coupling reaction on ferroferric oxide nanoparticles and (3-aminopropyl)-triethoxysilane in an organic solvent, washing, and drying to obtain aminated magnetic beads; and activating the aminated magnetic beads with glutaraldehyde, incubating with a snake venom phospholipase A2 solution, and reacting to obtain the magnetic bead immobilized snake venom phospholipase A2. The magnetic bead immobilized snake venom phospholipase A2 prepared by the invention can be used for rapidly and accurately fishing the snake venom phospholipase A2 toxin antidote from a mixture system, and has a better application prospect in the field of snake venom antidote research.

Disclosed are aptamers, aptamer antidotes, and their use in the treatment of thrombosis and other thrombotic conditions.

The invention relates to the technical field of pharmaceutical biology, aims to solve the problem of lack of specific detoxification drugs for treating glyphosate poisoning clinically, and particularly provides application of chlorogenic acid in preparation of drugs for treating glyphosate-induced renal toxicity diseases. The drug mechanism of the chlorogenic acid is as follows: glyphosate-induced renal toxicity is antagonized through targeted renal injury biomarkers, wherein the renal injury biomarkers comprise TIM-1, TIMP-2, IGFBP7 and LCN2. The invention also provides a preparation for preventing and / or relieving and / or treating glyphosate-induced renal toxicity diseases, wherein the preparation contains chlorogenic acid. The preparation can be a medicine, a pharmaceutical composition, a health care product, a food or an additive. The medicine prepared by the invention can be used for remarkably reducing the expression levels of TIM-1, TIMP-2, IGFBP7 and LCN2 of the GLY-induced renal injury. In addition, oxidative stress (LCN2), cell cycle arrest (TIMP-2 / IGFBP7) and inflammatory reaction (TIM-1) can be synchronously and accurately inhibited, and the curative effect is superior to that of a current single-channel medicine.

The invention discloses application of a compound SCH23390 in preparation of a medicine for treating lead poisoning, and relates to the technical field of medicines. The invention studies the efficacy of the compound SCH23390 in the treatment of lead poisoning, reveals the treatment effect of the compound SCH23390 on lead poisoning for the first time, breaks through the limitation of existing drug targets, directly corrects abnormal neural signals by inhibiting excessive activation of D1 neurons and avoids the side effect of central hyperexcitation, and has no obvious toxic or side effect under the treatment dosage, especially, the compound SCH23390 can be used for treating lead poisoning. The compound SCH23390 can obviously relieve specific abnormal behavior phenotypes caused by low-dose lead poisoning, and shows the nerve protection characteristic superior to that of a traditional chelating agent. The limitation that the traditional lead poisoning treatment field depends on a single chelating antidote is broken through, and a brand new direction is provided for developing multi-target and multi-mechanism anti-lead-toxicity drugs.

The invention discloses a nicotine substance antidote as well as a preparation method and application thereof, and particularly relates to application of methylene blue or salt thereof in preparation of an antidote for relieving thiamethoxam poisoning. Experiments prove that methylene blue or the salt thereof can effectively control, relieve and treat thiamethoxam poisoning symptoms, has a good detoxification effect and can prevent thiamethoxam poisoning in advance. Therefore, the methylene blue or the salt thereof provided by the invention can be used in the fields of medicines and the like, can effectively reduce death of birds and insect animals caused by thiamethoxam poisoning, stabilizes biologic chain circulation, and ensures the quality and yield of agricultural products.

The present invention discloses a composition for upper respiratory tract administration, which is used for the treatment and protection of fire injuries and contains a cyanide antidote and a metal chelating agent; with the appropriate carrier combination, the composition can be administered to the required individual in the form of a spray, an inhalant or a drop, etc. to prevent or treat the injuries caused by harmful substances at the fire scene.

The invention discloses preparation and application of a skeleton type vomitoxin antidote, and relates to the technical field of feed processing, and the skeleton type vomitoxin antidote is characterized in that the antidote is prepared from 60-70% of Na2S2O5 and 30-40% of a composite carrier through a hot melt extrusion instrument under the conditions that the sleeve outlet temperature is 60-80 DEG C and the screw rotating speed is 30-50 r / min. When the antidote is used for removing vomitoxin in mildewed corn, and the adding level of the effective component skeleton type SMBS is 0.1%, the using effect of the skeleton type vomitoxin antidote is optimal; when the antidote is used for removing DON (deoxynivalenol) in corn alcohol lees polluted by mycotoxin and the addition level of the effective component skeleton-type SMBS is 0.4%, the use effect of the skeleton-type vomitoxin antidote is optimal. A theoretical basis is provided for further development of the corn and the corn alcohol lees in the field of feed processing.

The present disclosure provides compositions and methods related to nucleic acid molecules having therapeutic aptamers. In particular, the present disclosure provides nucleic acids molecules comprising one or more aptamers having anticoagulant activity, as well as corresponding nucleic acid antidotes, for the modulation of blood coagulation in the context of disease and surgical intervention.

The present application belongs to the technical field of feed additives, and specifically provides a compound preparation for relieving selenium poisoning, which comprises taurine, vitamin E, glutathione, allicin and carotene. The compound preparation provided by the present application utilizes the synergistic effect among taurine, vitamin E, glutathione, allicin and carotene, replaces the commonly used intravenous injection of sodium thiosulfate antidote, slows down the absorption speed of selenium, relieves the oxidation of selenium to the lipid on the surface of liver cell membrane, and removes the by-products such as free radicals after selenium metabolism. By adopting sodium selenite to simulate the environment under acute high-concentration selenium exposure, it is proved that the compound preparation has certain relieving effect on the growth inhibition and liver damage caused by acute selenium poisoning.

The invention relates to a DNA (deoxyribonucleic acid) aptamer which is shown as a formula I and can be specifically combined with abrus precatorius toxin and exert inhibitory activity and application of the DNA aptamer in prevention or treatment of abrus precatorius toxin poisoning. The nucleic acid aptamer can be combined with the abrus precatorius toxin in a high-affinity and high-specificity mode, and the toxicity of the abrus precatorius toxin is effectively resisted. The invention also designs a pharmaceutical composition containing the nucleic acid aptamer sequence or the pharmaceutically acceptable salt thereof as an active ingredient, and an application of the nucleic acid aptamer sequence or the pharmaceutically acceptable salt thereof in preparation of an abrus precatorius toxin antidote drug. In addition, the nucleic acid aptamer can also be used for resisting the abrus precatorius toxin in vitro or used as a detection tool for detecting the abrus precatorius toxin in environmental and biological samples. The invention provides a new solution for first aid, treatment and detection of the abrus precatorius toxin.

The present invention relates to a detoxifying peptide, characterized in that its sequence comprises the following general amino acid sequence: N-(Val-Gly-X1-X2-Pro-Gly)n-OH, in which: N and OH correspond respectively to the N-terminal and C-terminal end of the peptide; X1 and X2 are chosen from valine (Val), glycine (Gly), threonine (Thr), asparagine (Asn), glutamine (Gln), alanine (Ala), leucine (Leu) and isoleucine (Ile); n is an integer between 1 and 3; for use in the treatment and / or prevention of a disorder associated with glycation and / or glycoxidation of proteins and / or lipids.

The invention provides application of beta-glucuronidase in preparation of an antidote for preventing or / and treating zearalenone poisoning and the antidote for preventing or / and treating zearalenone poisoning, and belongs to the field of feed additives. The invention provides a method for reducing the overall exposure level of ZEN by inhibiting the activity of intestinal bacteria beta-glucuronidase from the perspective of in-vivo exposure control of animals for the first time, and the method is clear in technical path and high in operability. The reduction of the in-vivo exposure level of the ZEN is objectively reflected through the change of in-vivo toxicokinetic parameters (AUC, Cmax and / or MRT), and the technical effect can be quantified and verified. The beta-glucuronidase inhibitor adopted by the invention is wide in source, is especially suitable for the field of feed additives, and has a good application prospect.

The invention provides a nano antibody for resisting a C-type botulinum toxin receptor binding domain and application of the nano antibody. The C-type botulinum toxin receptor binding domain is used as an antibody to immunize alpaca, RNA is extracted from mononuclear cells of the alpaca, and the nano antibody resisting the C-type botulinum toxin receptor binding domain is screened from the mononuclear cells by using a phage display library technology. The nano antibody provided by the invention can be specifically bound with a C-type botulinum toxin receptor binding domain, has high affinity, can effectively inhibit specific binding of C-type botulinum toxin and a target cell membrane, and can neutralize the C-type botulinum toxin to play a protective role. The nano antibody provided by the invention is expected to be applied to preparation of C-type botulinum toxin poisoning antidotes. Meanwhile, the nano antibody provided by the invention can be applied to qualitative and quantitative analysis and detection of C-type botulinum toxin as a capture antibody and a detection antibody.

The invention discloses a protection application of nicotinamide mononucleotide in APAP liver injury, and the nicotinamide mononucleotide is applied to preparation of a medicine for protecting or treating acetaminophen-induced acute liver injury. The nicotinamide mononucleotide reduces oxidative stress and liver cell apoptosis caused by acetaminophen by activating a nuclear factor erythrocyte 2 related factor 2 signal channel and inhibiting phosphorylation of c-Jun amino terminal kinase. Through dual mechanisms of activating an Nrf2 antioxidant pathway and inhibiting JNK phosphorylation, oxidative stress and cell apoptosis are relieved from the source, and the defect that an existing antidote NAC is narrow in treatment window is effectively overcome; the NMN is used as a direct precursor of NAD < + >, has good stability and high bioavailability, shows the effects of remarkably increasing the survival rate and improving liver functions and tissue pathological damage in experiments, and provides a brand-new multi-target treatment strategy for APAP poisoning.

The present invention relates to the field of biomedicine, and particularly to an oligocyclodextrin and its application in an antidote. The raw materials for preparing the oligocyclodextrin include β-cyclodextrin and a crosslinking agent; the molar ratio of the β-cyclodextrin to the crosslinking agent is 1:(8-30); the crosslinking agent is epichlorohydrin. The present invention prepares an oligocyclodextrin by reacting the crosslinking agent epichlorohydrin with β-cyclodextrin. It has both the characteristics of a monomeric cyclodextrin molecule and the characteristics of a polymer, and can detach the drug from the binding site on the FXa factor through the inclusion effect of the hydrophobic cavity, reversing its anticoagulant effect, so as to promote the recovery of normal blood coagulation function in a timely manner when the use of rivaroxaban is excessive. The oligocyclodextrin of the present invention has a reversing effect on a variety of oral anticoagulants, has a simple synthesis route, low raw material cost, and good biosafety when used in large doses, and can fill the gap in the lack of corresponding antidotes for oral anticoagulants.

A novel and useful respiratory monitoring system and related methods that can interact with an opioid user and initiate a lifesaving drug injection process to mitigate opioid induced respiratory depression in an opioid user when detected. The system employs a progressive challenge-response system to detect unresponsiveness, deliver physical stimuli, administer one or more doses of an antidote, and transmit notifications, thereby improving survival rates in overdose situations. The system and methods include a wearable device that acquires physiological information from an opioid user during an opioid use session, analyzes the information to detect respiratory depression in the opioid user, and initiates a lifesaving drug injection process when the presence of opioid induced respiratory depression is detected. Several methods are disclosed including self-monitoring and remote monitoring schemes that present a challenge to the opioid user with post injection stimulation of the opioid user and notification of caregivers and medical personnel.

The present invention relates to supramolecular agents presenting on demand reversibility of activity and related methods. The invention in particular relates to supramolecular agents with anticoagulant activity which can be reversed with the use of an antidote agent.

The present invention belongs to the field of pharmaceutical technology, and specifically relates to the application of indocyanine green in the treatment of amatoxin poisoning. In order to further search for a specific antidote for amatoxin poisoning, through in vitro cell, organoid experiments and in vivo mouse experiments, the present invention discovers that indocyanine green can reduce the killing effect of amatoxin on cells and block the cytotoxic effect of amatoxin on liver organoids. At the same time, it has a protective effect on mice poisoned by amatoxin, and can significantly reduce the liver and kidney damage caused by amatoxin poisoning in mice, and improve the long-term survival rate after poisoning. The present invention not only broadens the application field of indocyanine green, but also provides a new solution for amatoxin poisoning, provides a strong theoretical basis and practical basis for the further research and development of amatoxin antidote drugs, and has important research value and development significance.

The present disclosure provides compositions and methods related to nucleic acid molecules with therapeutic aptamers. Specifically, the present disclosure provides nucleic acid molecules comprising one or more aptamers having anticoagulant activity, and corresponding nucleic acid antidotes for modulating blood coagulation in the context of diseases and surgical interventions.

The present invention discloses a nicotinic substance antidote, its preparation method and application, in particular to the application of methylene blue or its salt in the preparation of an antidote for alleviating thiamethoxam poisoning. The present invention has verified through experiments that methylene blue or its salt can effectively control, alleviate and treat thiamethoxam poisoning symptoms, has a good detoxification effect, and can prevent thiamethoxam poisoning in advance. Therefore, the methylene blue or its salt provided by the present invention can be used in fields such as medicine, etc., can effectively reduce the death of animals such as birds and insects caused by thiamethoxam poisoning, stabilize the biological chain cycle, and ensure the quality and yield of agricultural products.